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Abstract
Purpose We have previously demonstrated in a pilot
study of 348 invasive breast cancers that mast cell (MC)
inﬁltrates within primary breast cancers are associated with
a good prognosis. Our aim was to verify this ﬁnding in a
larger cohort of invasive breast cancer patients and exam-
ine the relationship between the presence of MCs and other
clinical and pathological features.
Experimental design Clinically annotated tissue micro-
arrays (TMAs) containing 4,444 cases were constructed
and stained with c-Kit (CD-117) using standard immun-
operoxidase techniques to identify and quantify MCs. For
statistical analysis, we applied a split-sample validation
technique. Breast cancer speciﬁc survival was analyzed by
Kaplan–Meier [KM] method and log rank test was used to
compare survival curves.
Results Survival analysis by KM method showed that the
presence of stromal MCs was a favourable prognostic
factor in the training set (P=0.001), and the validation set
group (P=0.006). X-tile plot generated to deﬁne the
optimal number of MCs showed that the presence of any
number of stromal MCs predicted good prognosis. Multi-
variate analysis showed that the MC effect in the training
set (Hazard ratio [HR] = 0.804, 95% Conﬁdence interval
[CI], 0.653–0.991, P=0.041) and validation set analysis
(HR = 0.846, 95% CI, 0.683–1.049, P=0.128) was
independent of age, tumor grade, tumor size, lymph node,
ER and Her2 status.
Conclusions This study concludes that stromal MC
inﬁltration in invasive breast cancer is an independent good
prognostic marker and reiterates the critical role of local
inﬂammatory responses in breast cancer progression.
Keywords Breast cancer  Inﬂammatory inﬁltrate 
Mast cells  Stroma
Introduction
Mast cells (MCs) are part of the innate immune system and
are recruited to and activated in the microenvironment of a
developing tumor. MCs originate from multipotential
hemopoietic stem cells in the bone marrow, and express the
proto-oncogene c-kit, a transmembrane type III tyrosine
kinase receptor protein [1]. After leaving the vascular bed
they differentiate and acquire functional maturity.
MC inﬁltrates have been described in a variety of human
cancers, including non-small-cell lung cancer [2–4], breast
cancer [5], colorectal cancer [6], basal cell carcinoma [7]
and pulmonary adenocarcinoma [8]. MCs are attracted to
the tumor by tumor-derived chemo attractants where they
either degranulate to release potential tumor cytotoxic
compounds or become innocent bystanders depending on
local tumor conditions [9]. There is controversy about the
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cancers. The accumulation of MCs has been associated
with enhanced growth and invasion of several human
cancers [10]. On the other hand, MC inﬁltration has been
associated with good prognosis in breast [11, 12] ovarian
[13], lung [14] and colorectal [15] carcinomas.
Murine models have shown that tumor incidence and
growth are inversely correlated with the MC density in
MC-deﬁcient mice compared to normal [16].
Our previously published pilot report of 348 case series
of breast carcinomas showed that the presence of stromal
MCs correlated with a good prognosis (P=0.0036) in
invasive breast cancer [11].We present here a large tissue
microarray (TMA) study of 4,444 cases of invasive breast
carcinomas with clinical outcome data. This study vali-
dates the independent prognostic signiﬁcance of stromal
MCs in breast cancer.
Materials and methods
Patient selection
A total of 4,620 archival samples from patients with
invasive breast carcinoma referred to the British Columbia
Cancer Agency between January 1986 and September 1992
were used for TMA construction. The Clinical Research
Ethics Board of the University of British Columbia
approved the study. Patients with in-situ disease, metastatic
disease at presentation, and male breast cancer were
excluded from analysis, thus bringing the ﬁnal tally to
4,444 cases. This represents 34% of all patients diagnosed
with breast cancer in the province of British Columbia
during this time period. This large, well characterized co-
hort is derived from a consecutive series of patients who
were referred to the BC Cancer Agency for consultation
and had tumor samples sent to a central laboratory at the
Vancouver General Hospital for estrogen receptor (ER)
status. Consequently, for all of these patients we have
available detailed demographic and outcome data, as well
as formalin ﬁxed parafﬁn embedded (FFPE) primary tumor
samples for immunohistochemical analysis. Available
clinical information includes age, histology, tumor grade,
tumor size, lymph node status, type of local and adjuvant
systemic therapy, and dates of ﬁrst recurrence and death.
Clinical and pathological variables were determined
following well-established criteria. A portion of this cohort
of patients was recently used in a population study
validating the on-line breast cancer prognostic calculator
ADJUVANT! Online [17].
TMA construction
The Vancouver Hospital ER laboratory retained single
archival tumor blocks from each case in this patient cohort.
The material had been frozen prior to neutral buffered
formalin ﬁxation. All the parafﬁn sections were ﬁrst stained
with H&E and reviewed by a pathologist. Representative
tumor areas were circled and matched with the donor
blocks. 0.6-mm cores were punched out from the donor
blocks and embedded 1 mm apart in 17 recipient blocks
using Tissue Microarrayer (Beecher instruments Silver
Springs, MD). These tissue arrays have been used to test
the new ER SP1 antibody that improves the sensitivity for
detecting ER by IHC [18].
Immunohistochemistry (IHC)
Sections from TMA were cut at 4 lm and immunostained
with antibody to KIT (CD117), a transmembrane tyrosine
kinase acting as a type III receptor for MC growth factor.
Slides were also concurrently stained for ER and Her2
using standard immunoperoxidase techniques. The anti-
bodies and antigen retrieval methods are summarized in
Table 1.
Immunohistochemical image processing and scoring
The stained slides were digitally scanned with a BLISS
automated digital imaging microscope (Bacus Laboratories,
Lombard, IL) which consists of a microscope with a
scanning stage, video camera and software designed for
scanningTMAs.Arelationaldatabasewasconstructedusing
identiﬁcationinformationandimmunohistochemistryscores
for each tissue core in the microarrays. An internet website
was then constructed using this database and a WebSlide-
ViewerJavaappletprovidedbythemanufacturertoviewthe
microarray images and allow for an image zooming func-
tionality. This website is publicly accessible through http://
www.gpecimage.ubc.ca/tma/web/viewer.php.
Table 1 Details of antibodies
used for immunohistochemistry
Antibody Isotype Company Antigen retrieval Concentration
c-kit Rabbit polyclonal Dako Ventana 1:100
Her2 SP3 Rabbit monoclonal Lab vision Steam 30 min, 0.05 M TRIS buffer (pH 10) 1:100
ER SP1 Rabbit monoclonal Lab vision Citrate buffer (pH 6) 1:250
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123The slides were scored manually by two independent
pathologists, blinded to the clinical outcome, as previously
described [11]. Total number of stained MCs in each core
was recorded. ER status was assessed using the rabbit
monoclonal antibody (SP1) antibody [18]. The fractions
of ER positive tumor nuclei were scored as 0 (<1%), 1
(1–25%), 2 (25–75%), and 3 (>75%). Her2 SP3 rabbit
monoclonal from LabVision (NeoMarkers) was used to
stain the TMA slides and were scored using Hercept test
 
(Dako Corporation, Carpinteria, CA) scoring system. Final
Her2 score was derived using both IHC and Fluorescent
in situ hybridization (FISH) assays. Cases with Her2 IHC
Herceptest score = 3, were scored as positive. Those cases
with Her2 IHC Herceptest score = 2 were re-evaluated
using FISH assay, and only those cases with Her2 FISH
ampliﬁcation ratio ‡2.0 were scored as Her2 positive.
C-Kit and ER scores were binarized for statistical analysis
as follows: CD-117: 0 = no MCs; 1 = any MCs; ER:
0 £ 1% nuclei stained; 1 ‡ 1% nuclei stained. We
excluded cases for which it was not possible to assign a
score to the immunostaining (insufﬁcient invasive tumor in
the core, or missing core).
Statistical analysis
The raw scores were entered into an Excel database and
each TMA core was assigned a unique core ID number.
The spreadsheet was then processed utilizing TMA-
Deconvoluter 1.06 software that had been adapted for
TMA analysis [19]. A database was created by incorpora-
tion of all deconvoluted marker data into the clinicopath-
ologic patient database.
We applied a split-sample validation technique for our
statistical analysis. Our 4,444 patient cohort was strati-
ﬁed into eight subgroups (Table 2) based on adjuvant
treatment received and then randomized into equal sized
training and validation sets. The two groups were bal-
anced with respect to treatment received; but there are
also no signiﬁcant differences in clinical or pathological
variables, including age, tumor size and grade, nodal
status, and ER status. For this study, and future studies
using this TMA, the primary investigator is given access
to all clinical, outcome, and TMA data from the training
set only. The training set is used to generate and reﬁne
hypotheses regarding the biomarker under study. Signif-
icant ﬁndings are then formally presented at a bimonthly
joint scientiﬁc group meeting of the Genetic Pathology
Evaluation Centre (GPEC, a collaborative group of
scientists and pathologists) and Breast Cancer Outcomes
Unit (BCOU, a group of oncologists and epidemiologists
based at the BC Cancer Agency). Those ﬁndings
considered to be of clinical and scientiﬁc interest are
then re-tested on the validation set. A separate researcher
who did not participate in the training set analysis
performs the re-testing on the validation set. Our statis-
tical approach is intended to minimize false positive
results, particularly with subgroup analysis.
Statistical analysis was performed using SPSS 14.0. In
univariate analysis, breast-cancer speciﬁc survival (BCSS)
was estimated using Kaplan–Meier (KM) curves, and sig-
niﬁcant differences determined by Log rank tests. For
BCSS, survival time was censored at the date of death if
the cause was not breast cancer or at the date of last follow-
up if the patient was still alive at the end of the study
period. 6 patients with unknown cause of death were
excluded from BCSS analysis. Cox proportional hazards
models were used to calculate adjusted hazard ratios
accounting for covariates. Kendall’s tau-b and the
Mann-Whitney tests were used to measure the correlation
of c-kit status to pathological variables. All statistical tests
were two-sided. The Bonferroni correction for multiple
comparisons was applied during validation set analysis,
and the alpha value for each comparison is 0.05/n, where n
is the total number of comparisons.
X-tile analysis
We also used X-tile software [20] to ﬁnd the optimal
cut-off point for the total number of MCs that will predict
prognosis in breast cancer patients. X-tile program split the
cohort randomly into a matched training and validation set
as a method for selecting optimal cut-points. It than
calculated a P value for every possible division of the
cohort expression data. A two-dimensional graph with its
corresponding survival curves was plotted where each
colored pixel was proportional to is v
2 Value. The program
automatically calculated the maximum v
2 value which
served as a cut-point to separate the number of MCs that
predicted prognosis.
Results
Out of 4,620 cases on the TMAs, we selected 4,444 breast
cancers that showed invasive tumor in the cores. The cli-
nico-pathologic characteristics of patients included in the
study are depicted in Table 2. The total number of stained
MCs was recorded as a continuous variable with counts
ranging from 0 to 24 MCs per core. They were seen as
4–20 lm round to oval mononuclear cells with granular
cytoplasm and single oval nucleus. The cytoplasmic
granules were ganglion-, net-, or crystal-shaped (Fig. 1).
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Survival analysis
A total of 2,222 patients were included in the training set
analysis. After excluding cases which had insufﬁcient
invasive tumor, missing core or un-interpretable staining
pattern, 1,801 cases were carried forward for the analysis.
Out of these, MCs were present in 508 (28.2%) cases. The
mean survival time of patients with presence of stromal
MCs was 15.0 years (95% CI, 14.5–15.5) compared to
13.9 years (95% CI, 13.5–14.2) for those who did not have
positively stained MCs in their tumor stroma. KM survival
analysis (Fig. 2a) showed that the presence of stromal MCs
Table 2 Summary of clinical-
pathological characteristics of
the 4,444 breast cancer patients
Test set Validation set
n %
within
group
% within
known
values
n %
within
group
% within
known
values
Total 2,222 2,222
Age at diagnosis (years)
Median
(range)
60 (25–95) 60 (23–91)
<40 170 7.7 7.7 157 7.1 7.1
40–54 457 20.6 20.6 468 21.1 21.1
55–69 702 31.6 31.6 809 36.4 36.4
‡70 893 40.2 40.2 788 35.5 35.5
Gender
Female 2,211 99.5 99.5 2,210 99.5 99.5
Male 11 0.5 0.5 10 0.5 0.5
Nodal status
Negative 1,272 57.2 57.4 1,256 56.5 56.8
Positive 943 42.4 42.6 957 43.1 43.2
Unknown 7 0.3 9 0.4
Number of positive nodes
Median
(range)
2 (1–24) 2 (1–28)
1–3 586 62.1 64.3 614 64.2 66.2
4–9 243 25.8 26.7 229 23.9 24.7
‡10 82 8.7 9.0 84 8.8 9.1
Unknown 32 3.4 30 3.1
ER Status at diagnosis
Negative 472 21.2 21.8 472 21.2 21.9
Positive 1,689 76.0 78.2 1,687 75.9 78.1
Unknown 61 2.7 63 2.8
Tumor size (cm)
Median
(range)
2.0 (0.1–9.9) 2.0 (0.1–9.9)
0.1–1.0 265 11.9 12.1 285 12.8 13.0
1.1–2.0 864 38.9 39.4 864 38.9 39.5
2.1–5.0 949 42.7 43.2 915 41.2 41.8
>5.0 117 5.3 5.3 126 5.7 5.8
Unknown 27 1.2 32 1.4
Tumor grade
1 125 5.6 6.0 103 4.6 4.9
2 876 39.4 42.0 844 38.0 40.2
3 1,083 48.7 52.0 1,153 51.9 54.9
Unknown 138 6.2 122 5.5
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123was a favourable prognostic marker in the entire training
set (BCSS @ 18.4 years, Log rank [Mantel Cox],
P=0.001).
Correlation with other biomarkers
There was positive correlation between MCs and ER
(Kendall’s tau-b [sb], 0.034, P=0.148), Bcl2 (sb = 0.077,
P=0.002), and Her2 (sb = 0.049, P=0.052), and nega-
tive correlation between MCs and EGFR (sb = –0.029,
P=0.228) and CK5/6 (sb = –0.003, P=0.906) in the
training set analysis (Table 3). As these correlations were
either not signiﬁcant or extremely weak, they were not
carried forward to the validation set for further analysis.
Nodal status
KM survival analysis showed no statistically signiﬁcant
difference in the survival between tumors with and without
MCs in node-negative (BCSS @ 18.1 years, Log rank
[Mantel Cox], P=0.1199) and a signiﬁcant difference in
the node-positive group (BCSS @ 18.3 years, Log rank
[Mantel Cox], P=0.0140). Hence, this result was also not
carried forward to the validation set.
Multivariate analysis
Cox proportional hazard model was used to carry out the
multivariate analysis and included age, tumor grade, tumor
size, nodal status, ER and Her2 as independent predictors
of BCSS. All the above variables achieved statistical
signiﬁcance as shown in Table 4(a). Presence of MCs
achieved statistical signiﬁcance (P=0.041) with a
HR = 0.804, 95% CI 0.653–0.991.
Validation set results
Survival analysis
This group included the remaining 2,222 patients from the
whole cohort. The mean age at diagnosis was 60 years and
the median follow-up was 12.4 years. The median tumor
size was 2.0 cm. 50% of patients had Grade 3 tumors, 43%
were node positive, and 76% were ER positive. After
excluding cases that had insufﬁcient invasive tumor,
missing core or un-interpretable staining pattern, 1,796
cases were carried forward for the analysis. Out of these,
MCs were present in 494 (27.5%) cases. KM survival
analysis (Fig. 2b) showed that the presence of stromal MCs
Fig. 1 TMA core showing stromal mast cells stained with c-kit (CD-
117). Magniﬁcation, 20·. MCs are seen as brown, granular stained
oval, spindle or polygonal cells
Fig. 2 KM survival curve for all patients in training set (a) and
validation set (b) with presence of stromal mast cells
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123was a favourable prognostic marker in the validation set
(P=0.006).
Multivariate analysis
Cox proportional hazard model was used to carry out the
multivariate analysis and included age, tumor grade, tumor
size, nodal status, ER and Her2 as independent predictors
of BCSS. All the above variables achieved statistical
signiﬁcance as shown in Table 4(b). Presence of MCs did
not achieve statistical signiﬁcance (P=0.128) but retained
a similar HR = 0.846, 95% CI 0.683–1.049 as in the
training set analysis.
X-tile analysis results
We assessed the association between patient outcome and
number of positively stained MCs in the stroma of tumors
using X-tile software. This software allowed us to deﬁne an
optimal cut-off point that deﬁned the number of MCs
needed to predict good prognosis in the cancer patients.
The program divided the population into low and high-risk
groups based on the number of MCs detected. It converted
continuous data into ordinal classes for statistical analysis.
The X-tile plot showed that breast cancer patients with any
number of stromal MCs had better prognosis compared to
those who have no MC inﬁltration in their stroma. MCs
ranging between 1 and 22 in the tumor stroma were present
in 507 (27.61%) patients and were grouped together in the
low population group of the training set. The high popu-
lation group comprised of 1,329 (72.39%) patients in the
training set. It reiterated the ﬁndings obtained by KM
survival analysis that the presence of any number of stro-
mal MCs predicts good prognosis in invasive breast cancer
patients.
Discussion
The importance of the reciprocal relationship between tu-
mor and stroma is being increasingly recognized [21], and
is the role of stromal inﬂammatory cells like MCs,
macrophages, ﬁbroblasts and T cell subtypes in cancer
initiation and progression. cDNA microarray analysis has
shown that genes expressed by stromal cells correlate with
differences in the biology of the tumors and are prognostic
predictors in breast cancer [22].
There is an ongoing debate about possible detrimental or
beneﬁcial effects of MC accumulation in the stroma of
solid tumors. In-vitro studies have shown that MC inhibits
tumor growth [23]. This is in agreement with other studies
showing increase in MC count in early stage of non-small
cell lung cancer and thereby supporting their anti-tumor
role. [3]. Increased islet/stromal MC-ratio and presence of
tumor islet MCs were shown to be independent good
prognostic indicators in non-small-cell lung cancer [24].
Recent studies in ovarian cancer [13] and colorectal cancer
[15] have also conﬁrmed their correlation with prognosis.
MCs secrete factors like heparin, interleukin-8 (IL-8)
and vascular endothelial growth factor that promote neo-
vascularization; histamine which suppresses immune re-
sponse; platelet-derived growth factor, nerve growth factor
and stem-cell factors which are mitogenic; and proteases
that promote metastasis [9]. On the other hand, MCs can
inhibit tumor growth by releasing endogenous peroxidase
that is cytotoxic to mammalian tumor cells [25], by natural
cytotoxicity [21] and by recruiting neutrophils, eosinophils,
lymphocytes and macrophages [26]. MCs can secrete
protective substances without degranulation in the presence
of tumor-derived blockers like oxidized polyamines and
thus be detrimental to the tumor [27]. They can destroy
tumor cell surface structures directly and indirectly in a
fashion similar to the effect of arginase [28]. MCs can also
inhibit tumor growth by secreting beneﬁcial cytokines like
IL-1, IL-4, IL-6, and tumor necrosis factor-a that induce
apoptosis of endothelial cells [29]; and chondroitin
sulphate which inhibits metastases [30]. Cathepsin G
secreted by MC activates platelets, lymphocytes and
macrophages, and is known to be cytotoxic to some
mammalian cells [31]. Its inhibition by a tumor cell
product was implicated in the progression of advanced
squamous cell tumors [32] suggesting its cytotoxic capa-
bility against target cells. MCs secrete chymase, which
stimulates apoptosis in different target cells [33] and
Table 3 Correlations between mast cells and other biomarkers
Training set Mast cells
ER Kendall’s tau-b 0.034
Signiﬁcance (2-tailed) 0.148
N 1,788
EGFR Kendall’s tau-b –0.029
Signiﬁcance (2-tailed) 0.228
N 1,646
Her2 Kendall’s tau-b 0.049
Signiﬁcance (2-tailed) 0.052
N 1,746
CK5/6 Kendall’s tau-b –0.003
Signiﬁcance (2-tailed) 0.906
N 1,624
Bcl2 Kendall’s tau-b 0.077
Signiﬁcance (2-tailed) 0.002
N 1,616
N—scorable for both markers
All scores binarized as detailed in the text
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123inhibits angiogenesis by exerting cytotoxic effect on
vascular smooth muscles [34]. MC tryptase stimulates
inﬂammation and recruits ﬁbroblasts leading to tumor
ﬁbrosis, and thereby limiting tumor growth and metastasis
[35]. Tryptase, however, is also implicated in angiogene-
sis and its effect correlated with a better response to
chemotherapy in ovarian cancer. This suggests that MC
tryptase-mediated ﬁbrosis and angiogenesis may be
responsible for the good prognostic effect seen in advanced
ovarian cancer [13].
In this TMA study, we showed that the presence of even
one or more MCs in the tumor microenvironment was
sufﬁcient to exert a positive prognostic effect. Our ﬁnding
supports the idea of assessing inﬂammatory cell inﬁltrates
as prognostic markers in cancer. In our previously pub-
lished pilot report, we had observed no correlation between
the presence of stromal MCs with either B-cells (CD20-
positive) or T-cells (CD3-positive) [11], and hence we did
not stain for these inﬂammatory cells in this study. We also
did not ﬁnd a statistically signiﬁcant prognostic effect of
MCs in the node-negative groups in the training set anal-
ysis. This differs from our earlier published report [11]o na
348 case series which concluded that the presence of MCs
was a favourable prognostic factor in the node-negative
patients (P=0.018) but not the node-positive group
(P=0.384). This ﬁnding underscores the importance of
validating clinically relevant ﬁndings on a larger series of
patients and using the test-validation approach to arrive at a
meaningful conclusion.
A number of studies have elaborated on the role of
immune cells in cancer etiopathogenesis. T regulatory
(Treg) cells are known to be associated with poor outcome
in ovarian cancer [36] and the initial results of a clinical
trial aimed at speciﬁcally eliminating Treg cells has shown
promising results [37]. Lymphoma-associated macrophag-
es have been used to predict the outcome of follicular
lymphoma [38] and reactive macrophages are used to
predict breast, prostate, ovarian, and cervical cancer
Table 4 Cox proportional
hazard regression analysis
showing hazard ratios and P-
values in patients with invasive
breast carcinoma
* Grade 1—well differentiated
Grade 2—moderately
differentiated
Grade 3—poorly differentiated
HR = adjusted hazard ratio,
CI = conﬁdence interval and
BCSS = Breast Cancer Speciﬁc
Survival
Signiﬁcance HR BCSS 95% CI for HR
Lower Upper
(a) Training set
Mast cells 0.041 0.804 0.653 0.991
ER 0.018 0.777 0.631 0.957
Her2 0.003 1.439 1.129 1.834
Size of the lesion
2–5 cm vs. £2 cm 0.000 1.884 1.547 2.295
>5 cm vs. £2 cm 0.001 1.931 1.330 2.803
Grade*
Grade 1, 2 vs. Grade 3 0.001 1.390 1.139 1.696
Nodal status 0.000 2.380 1.965 2.882
Age
40–49 vs. <40 0.000 0.567 0.420 0.765
50–65 vs. <40 0.013 0.689 0.513 0.924
>65 vs. <40 0.019 0.677 0.489 0.938
(b) Validation set
Mast cells 0.128 0.846 0.683 1.049
ER 0.0289 0.793 0 .644 0 .976
Her2 0.0018 1.463 1.152 1.859
Size of the lesion
2–5 cm vs. £2 cm 3.07 · 10
–4 1.439 1.181 1.753
>5 cm vs. £2 cm 1.66 · 10
–6 2.258 1.618 3.151
Grade*
Grade 1, 2 vs. Grade 3 1.96 · 10
–6 1.658 1.346 2.042
Nodal status 7.06 · 10
–19 2.410 1.984 2.927
Age
40–49 vs. <40 0.432 1.158 0.803 1.671
50–65 vs. <40 0.634 1.090 0.765 1.552
>65 vs. <40 0.07 1.394 0.973 1.998
Breast Cancer Res Treat (2008) 107:249–257 255
123outcome [39]. Tumor-inﬁltrating neutrophils are used to
predict outcome in patients with adenocarcinoma of the
bronchioloalveolar carcinoma subtype [40] and gastric
carcinoma [41]. In a recent report, it was concluded that the
type, density, and location of immune cells within the tu-
mor samples are a better predictor of patient survival than
the histopathological methods currently used to stage
colorectal cancer [42].
In conclusion, we conﬁrm our earlier pilot study ﬁndings
and conﬁrm that stromal MCs correlate with a good
prognosis in a large cohort of 4,444 invasive breast cancer
patients with long-term follow-up. It highlights the critical
role that the host stromal reaction, in particular the
inﬂammatory cell inﬁltrate, plays in modulating cancer
progression. MCs can be used as markers for risk stratiﬁ-
cation in invasive breast cancers.
Acknowledgements This work was supported in part by the
Canadian Institutes of Health Research Strategic Training Program
(Grant STP-53912), Translation Acceleration Grant from the Cana-
dian Breast Cancer Research Alliance and the National Institute of
Health Strategic Partnering to Evaluate Cancer Signatures program.
The Genetic Pathology Evaluation Center is supported by an unre-
stricted educational grant from sanoﬁ-aventis, Canada. D. Huntsman
and T. Nielsen are Michael Smith Health Foundation for Research
Scholars.
References
1. Baek JY, Tefferi A, Pardanani A, Li CY (2002) Immunohisto-
chemical studies of c-kit, transforming growth factor-beta, and
basic ﬁbroblast growth factor in mast cell disease. Leuk Res
26:83–90
2. Shijubo N, Kojima H, Nagata M, Ohchi T, Suzuki A, Abe S, Sato
N (2003) Tumor angiogenesis of non-small cell lung cancer.
Microsc Res Tech 60:186-198
3. Ibaraki T, Muramatsu M, Takai S, Jin D, Maruyama H, Orino T,
Katsumata T, Miyazaki M (2005) The relationship of tryptase-
and chymase-positive mast cells to angiogenesis in stage I non-
small cell lung cancer. Eur J Cardiothorac Surg 28:617–621
4. Tataroglu C, Kargi A, Ozkal S, Esrefoglu N, Akkoclu A (2004)
Association of macrophages, mast cells and eosinophil leuko-
cytes with angiogenesis and tumor stage in non-small cell lung
carcinomas (NSCLC). Lung Cancer 43:47–54
5. Kankkunen JP, Harvima IT, Naukkarinen A (1997) Quantitative
analysis of tryptase and chymase containing mast cells in benign
and malignant breast lesions. Int J Cancer 72:385–388
6. Lachter J, Stein M, Lichtig C, Eidelman S, Munichor M (1995)
Mast cells in colorectal neoplasias and premalignant disorders.
Dis Colon Rectum 38:290–293
7. Yamamoto T, Katayama I, Nishioka K (1997) Expression of stem
cell factor in basal cell carcinoma. Br J Dermatol 137:709–713
8. Imada A, Shijubo N, Kojima H, Abe S (2000) Mast cells correlate
with angiogenesis and poor outcome in stage I lung adenocarci-
noma. Eur Respir 15:1087–1093
9. Theoharides CT, Conti P (2004) Mast cells: the JEKYLL and
HYDE of tumor growth. Trends Immunol 25:235–241
10. Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L, Dammacco
F (2001) The role of mast cells in tumour angiogenesis. Br J
Haematol 115:514–521
11. Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik
C, Gelmon K, Chia S, Hayes M (2004) The presence of stromal
mast cells identiﬁes a subset of invasive breast cancers with a
favourable prognosis. Mod Pathol 17:690–695
12. Aaltomaa S, Lipponen P, Papinaho S, Kosma VM (1993) Mast
cells in breast cancer. Anticancer Res 13:785–788
13. Chan JK, Loizzi V, Magistris A, Hunter MI, Rutgers J, DiSaia PJ,
Berman ML (2005) Mast cell density, angiogenesis, blood clot-
ting, and prognosis in women with advanced ovarian cancer.
Gynecol Oncol 99:20–25
14. Tomita M, Matsuzaki Y, Onitsuka T (1999) Correlation between
mast cells, survival rates in patients with pulmonary adenocar-
cinoma. Lung Cancer 26:103–108
15. Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y, Zhao LJ (2005)
Prognostic signiﬁcance of cell inﬁltrations of immunosurveil-
lance in colorectal cancer. World J Gastroenterol 11:1210–1214
16. Burtin C, Ponvert C, Fray A, Scheinmann P, Lespinats G, Lori-
don B, Canu P, Paupe J (1985) Inverse correlation between tumor
incidence and tissue histamine levels in W/WV, WV/+, and +/+
mice. J Natl Cancer Inst 74:671–674
17. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ,
Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-
based validation of the prognostic model ADJUVANT! for early
breast cancer. J Clin Oncol 23:2716–2725
18. Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD,
Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB,
Nielsen TO, Gown AM (2006) Immunohistochemical detection
using the new rabbit monoclonal antibody SP1 of estrogen
receptor in breast cancer is superior to mouse monoclonal anti-
body 1D5 in predicting survival. J Clin Oncol 24:5637–5644
19. Liu CL, Prapong W, Natkunam Y, Alizadeh A, Montgomery K,
Gilks CB, van de Rijn M (2002) Software tools for high-
throughput analysis and archiving of immunohistochemistry
staining data obtained with tissue microarrays. Am J Pathol
161:1557–1565
20. Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-
informatics tool for biomarker assessment and outcome-based
cut-point optimization. Clin Cancer Res 10:7252–7259
21. Bhowmick AN, Moses LH (2005) Tumor-stroma interactions.
Curr Opin Genet Dev 15:97–101
22. West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL,
Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard
T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M
(2005) Determination of stromal signatures in breast carcinoma.
PLoS Biol 3:e187
23. Ghiara P, Boraschi D, Villa L, Scapigliati G, Taddei C, Tagliabue
(1985) In vitro generated mast cells express natural cytotoxicity
against tumour cells. Immunology 55:317–324
24. Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ,
Bradding P (2005) Macrophage and mast-cell invasion of tumor
cell islets confers a marked survival advantage in non-small-cell
lung cancer. J Clin Oncol 23:8959–8967
25. Henderson WR, Chi EY, Jong EC, Klebanoff SJ (1981) Mast
cell-mediated tumor-cell cytotoxicity. Role of the peroxidase
system. J Exp Med 153:520–533
26. He S, Walls AF (1998) Human mast cell chymase induces the
accumulation of neutrophils, eosinophils and other inﬂammatory
cells in vivo. Br J Pharmacol 125:1491–1500
27. Vliagoftis H, Boucher WS, Mak LL, Theoharides CT (1992)
Inhibition of mast cell secretion by oxidation products of natural
polyamines. Biochem Pharmacol 43:2237–2245
28. Farram E, Nelson DS (1980) Mouse mast cells as anti-tumor
effector cells. Cell Immunol 55:294–301
29. Latti S, Leskinen M, Shiota N, Wang Y, Kovanen PT, Lind-
stedt KA (2003) Mast cell-mediated apoptosis of endothelial
cells in vitro: a paracrine mechanism involving TNF-alpha-
256 Breast Cancer Res Treat (2008) 107:249–257
123mediated down-regulation of bcl-2 expression. J Cell Physiol
195:130–138
30. Kokenyesi R (2001) Ovarian carcinoma cells synthesize both
chondroitin sulfate and heparan sulfate cell surface proteoglycans
that mediate cell adhesion to interstitial matrix. J Cell Biochem
83:259–270
31. Johnson RJ, Couser WG, Alpers CE, Vissers M, Schulze M,
Klebanoff SJ (1988) The human neutrophil serine proteinases,
elastase and cathepsin G, can mediate glomerular injury in vivo. J
Exp Med 168:1169–1174
32. Schick C, Kamachi Y, Bartuski AJ, Cataltepe S, Schechter NM,
Pemberton PA, Silverman GA (1997) Squamous cell carcinoma
antigen 2 is a novel serpin that inhibits the chymotrypsin-like
proteinases cathepsin G and mast cell chymase. J Biol Chem
272:1849–1855
33. Hara M, Matsumori A, Ono K, Kido H, Hwang MW, Mi-
yamoto T, Iwasaki A, Okada M, Nakatani K, Sasayama S
(1999) Mast cells cause apoptosis of cardiomyocytes and
proliferation of other intramyocardial cells in vitro. Circulation
100:1443–1449
34. Leskinen MJ, Lindstedt KA, Wang Y, Kovanen PT (2003) Mast
cell chymase induces smooth muscle cell apoptosis by a mech-
anism involving ﬁbronectin degradation and disruption of focal
adhesions. Arterioscler Thromb Vasc Biol 23:238–243
35. Ruoss SJ, Hartmann T, Caughey GH (1991) Mast cell tryptase is
a mitogen for cultured ﬁbroblasts. J Clin Invest 88:493–499
36. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P,
Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu
Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A,
Disis ML, Knutson KL, Chen L, Zou W (2004) Speciﬁc
recruitment of regulatory T cells in ovarian carcinoma fosters
immune privilege and predicts reduced survival. Nat Med
10:942–949
37. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D,
Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J (2005)
Enhancement of vaccine-mediated antitumor immunity in cancer
patients after depletion of regulatory T cells. J Clin Invest
115:3623–3633
38. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ,
Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD (2005)
Analysis of multiple biomarkers shows that lymphoma-associated
macrophage (LAM) content is an independent predictor of sur-
vival in follicular lymphoma (FL). Blood 106:2169–2174
39. Pollard JW (2004) Tumour-educated macrophages promote tu-
mour progression and metastasis. Nat Rev Cancer 4:71–78
40. Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Ber-
naudin JF, Mayaud C, Milleron B, Baud L, Cadranel J (1998)
Neutrophil alveolitis in bronchioloalveolar carcinoma: induction
by tumor-derived interleukin-8 and relation to clinical outcome.
Am J Pathol 152:83–92
41. Caruso RA, Bellocco R, Pagano M, Bertoli G, Rigoli L, Inferrera
C (2002) Prognostic value of intratumoral neutrophils in ad-
vanced gastric carcinoma in a high-risk area in northern Italy.
Mod Pathol 15:831–837
42. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B,
Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P,
Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman
WH, Pages F (2006) Type, density, and location of immune cells
within human colorectal tumors predict clinical outcome. Science
313:1960–1964
Breast Cancer Res Treat (2008) 107:249–257 257
123